PeptidePedia The community reference

Contributions of NauseaNoor

User contributions·18 logged edits·page 1 of 1

Contributions by NauseaNoor, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 7,238 edits includes activity predating the current log.

  1. 05:19, 21 Mar 2026 (diff | hist) International nonproprietary name 4,356 ±0 reorder the analogues chronologically rather than alphabetically
  2. 09:45, 6 Feb 2026 (diff | hist) Talk:Adverse effects of GLP-1 receptor agonists 400 +161 /* Placebo-arm nausea */ new section
  3. 06:29, 31 Jan 2026 (diff | hist) Medutest 5,018 ±0 m label the community tally as self-reported at this point of use as well
  4. 22:52, 15 Jan 2026 (diff | hist) Trial data comparison 7,303 ±0 add the assumed syringe scale to the readout label
  5. 01:24, 1 Jan 2026 (diff | hist) Reverse-phase HPLC 5,499 ±0 m add the forced-degradation conditions the claim rests on
  6. 18:00, 23 Oct 2025 (diff | hist) Peptide synthesis 5,649 ±0 add the collapse-temperature point, sourced
  7. 13:54, 6 Jun 2025 (diff | hist) SURPASS trial programme 4,474 ±0 m the percentage quoted was placebo-adjusted; label it
  8. 21:26, 8 May 2025 (diff | hist) Hypoglycaemia 3,775 +32 clarify that dose-dependence is reported for some effects and not others
  9. 18:31, 7 May 2025 (diff | hist) Prescribing information 4,324 +641 add the note that list price is rarely what is paid
  10. 04:20, 22 Apr 2025 (diff | hist) Enteroendocrine L cell 4,648 +29 m expand §GLP-1 synthesis and secretion
  11. 04:40, 5 Feb 2025 (diff | hist) Weight regain after discontinuation 3,696 +126 m add the note that titration exists partly to manage these effects
  12. 02:43, 26 Jan 2025 (diff | hist) Reconstitution calculator 4,456 +151 add keyboard operation to the control description
  13. 16:41, 20 Jan 2025 (diff | hist) Injection site rotation 3,555 +586 state the assumption that the whole vial is reconstituted at once
  14. 18:12, 10 Jan 2025 (diff | hist) Liquid chromatography-mass spectrometry 3,315 +673 clarify the difference between related substances and total impurities
  15. 06:30, 31 Dec 2024 (diff | hist) Contraindications of incretin therapy 2,653 ±0 m state whether the figure is from a trial or from post-marketing reporting
  16. 12:54, 22 Dec 2024 (diff | hist) Sterility testing 2,614 ±0 fix indentation in the source
  17. 16:16, 20 Nov 2024 (diff | hist) Peptide content 3,952 +429 add category for method validation
  18. 09:58, 10 Nov 2024 (diff | hist) Survodutide 1,456 ±0 ce per PP:MOS